Sensipar Exclusivity Expires, Ending Amgen's DC Circ. Fight
Amgen Inc. and the U.S. Food and Drug Administration have asked the D.C. Circuit to end their case debating whether the drugmaker should get extended exclusivity for its blockbuster calcium-control drug...To view the full article, register now.
Already a subscriber? Click here to view full article